SCHEMBL4741010

SCHEMBL4741010

COc1ccc2c(c1)c(Nc1cccc(Cl)c1)nn2CC(=O)N(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FADS1 O60427 2/20 0.48
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
HPGD P15428 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
LMNA P02545 1/20 0.46
GFER P55789 1/20 0.46
AKR1C3 P42330 1/20 0.45
AKR1C2 P52895 1/20 0.45
TNK2 Q07912 1/20 0.43
KDR P35968 2/20 0.43
MAPT P10636 2/20 0.42
RXFP1 Q9HBX9 2/20 0.42
CLK1 P49759 1/20 0.42
CLK2 P49760 1/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
POLB P06746 1/20 0.42
PTGS2 P35354 1/20 0.41
MAOB P27338 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4740979 0.88 FADS1 (0.50) FADS1MEN1KMT2AHPGDSMN1; SMN2
SCHEMBL4740978 0.87 FADS1 (0.49) FADS1MEN1KMT2AHPGDSMN1; SMN2
SCHEMBL4934407 0.86 AURKA (0.49) FADS1MEN1KMT2AHPGDSMN1; SMN2
SCHEMBL4741979 0.86 FADS1 (0.48) FADS1MEN1KMT2AHPGDSMN1; SMN2
SCHEMBL4740936 0.83 FADS1 (0.49) FADS1MEN1KMT2AHPGDSMN1; SMN2
SCHEMBL4937692 0.83 FADS1 (0.46) FADS1MEN1KMT2AHPGDSMN1; SMN2
SCHEMBL4741728 0.83 FADS1 (0.55) FADS1MEN1KMT2AHPGDSMN1; SMN2
SCHEMBL4785627 0.82 KDR (0.54) FADS1MEN1KMT2AHPGDSMN1; SMN2
SCHEMBL4785821 0.81 FADS1 (0.51) FADS1MEN1KMT2AHPGDSMN1; SMN2
SCHEMBL4739356 0.81 FADS1 (0.51) FADS1MEN1KMT2AHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008089310-A2 DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY LEXICON PHARMACEUTICALS, INC. (US) 2008-07-24 WO claimed
WO-2008089307-A2 DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER LEXICON PHARMACEUTICALS, INC. (US) 2008-07-24 WO claimed
US-20080200458-A1 Methods and compositions for the treatment of body composition disorders LEXICON PHARMACEUTICALS, INC. 2008-08-21 US disclosed
US-20080194557-A1 Methods and compositions for the treatment of pain, inflammation and cancer LEXICON PHARMACEUTICALS, INC. 2008-08-14 US disclosed
WO-2008089310-A2 DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY LEXICON PHARMACEUTICALS, INC. (US) 2008-07-24 WO disclosed
WO-2008089307-A2 DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER LEXICON PHARMACEUTICALS, INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194557-A1 Methods and compositions for the treatment of pain, inflammation and cancer TNF, IL6, CXCL8 FADS1 1059/4885MEN1 3245/4885KMT2A 3920/4885
US-20080200458-A1 Methods and compositions for the treatment of body composition disorders CPT1B, CPT1A, SHBG FADS1 270/4885MEN1 1919/4885KMT2A 3148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.